Literature DB >> 15679049

Osteopontin regulates multiple functions contributing to human colon cancer development and progression.

R B Irby1, S M McCarthy, T J Yeatman.   

Abstract

Osteopontin (OPN) is a secreted phosphoglycoprotein known to interact with a number of integrin receptors. While increased OPN expression has been reported in a number of human cancers, and its cognate receptors (alphav-beta3, alphav-beta5, and alphav-beta1 integrins and CD44) have been identified, its role in colon cancer development and progression has not been extensively studied. We previously identified, using a combination of gene expression and tissue microarrays, that increased OPN expression is concordant with tumor stage. The current study examined the functional role of OPN in colon cancer progression and metastatic potential. The principal findings of this study were that both endogenous OPN expression (via stable transfection) as well as exogenous OPN (added to culture medium) enhanced the motility and invasive capacity of human colon cancer cells in vitro. OPN appeared to regulate motility though interaction with CD44. OPN expression also reduced intercellular (homotypic) adhesion, an important characteristic of metastatic cancer cells. Stable transfection of four poorly tumorigenic human colon cancer cell lines with OPN also resulted in enhanced tumorigenicity in vivo with increased proliferation and increased CD31 positive microvessel counts, concordant with the degree of OPN expression. Collectively, these results suggest that OPN may affect multiple functional components contributing to human colon cancer progression and solidifies its role in this process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15679049     DOI: 10.1007/s10585-004-2873-4

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  28 in total

1.  Osteopontin stimulates a subpopulation of quiescent human prostate epithelial cells with high proliferative potential to divide in vitro.

Authors:  A Elgavish; C Prince; P L Chang; K Lloyd; R Lindsey; R Reed
Journal:  Prostate       Date:  1998-05       Impact factor: 4.104

2.  Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma.

Authors:  N Shijubo; T Uede; S Kon; M Maeda; T Segawa; A Imada; M Hirasawa; S Abe
Journal:  Am J Respir Crit Care Med       Date:  1999-10       Impact factor: 21.405

3.  Osteopontin: possible role in prostate cancer progression.

Authors:  G N Thalmann; R A Sikes; R E Devoll; J A Kiefer; R Markwalder; I Klima; C M Farach-Carson; U E Studer; L W Chung
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

4.  Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.

Authors:  Deepak Agrawal; Tingan Chen; Rosalyn Irby; John Quackenbush; Ann F Chambers; Marianna Szabo; Alan Cantor; Domenico Coppola; Timothy J Yeatman
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

5.  Developmental expression of osteopontin (OPN) mRNA in rat tissues: evidence for a role for OPN in bone formation and resorption.

Authors:  J Chen; K Singh; B B Mukherjee; J Sodek
Journal:  Matrix       Date:  1993-03

6.  Non-RGD domains of osteopontin promote cell adhesion without involving alpha v integrins.

Authors:  Y U Katagiri; M Murakami; K Mori; J Iizuka; T Hara; K Tanaka; W Y Jia; A F Chambers; T Uede
Journal:  J Cell Biochem       Date:  1996-07       Impact factor: 4.429

7.  The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro.

Authors:  L Liaw; M P Skinner; E W Raines; R Ross; D A Cheresh; S M Schwartz; C M Giachelli
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

8.  Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration.

Authors:  Toshiyuki Murai; Yoshihiro Miyazaki; Hitomi Nishinakamura; Kazuki N Sugahara; Takayuki Miyauchi; Yasushi Sako; Toshio Yanagida; Masayuki Miyasaka
Journal:  J Biol Chem       Date:  2003-11-17       Impact factor: 5.157

9.  Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma.

Authors:  Gabriele Carlinfante; Daphne Vassiliou; Olle Svensson; Mikael Wendel; Dick Heinegård; Göran Andersson
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

10.  Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression.

Authors:  S Takano; K Tsuboi; Y Tomono; Y Mitsui; T Nose
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

View more
  29 in total

1.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

2.  Differential gene expression and functional analysis implicate novel mechanisms in enteric nervous system precursor migration and neuritogenesis.

Authors:  Bhupinder P S Vohra; Keiji Tsuji; Mayumi Nagashimada; Toshihiro Uesaka; Daniel Wind; Ming Fu; Jennifer Armon; Hideki Enomoto; Robert O Heuckeroth
Journal:  Dev Biol       Date:  2006-06-27       Impact factor: 3.582

3.  Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner.

Authors:  Renee J Phillips; Karla J Helbig; Kylie H Van der Hoek; Devanshi Seth; Michael R Beard
Journal:  World J Gastroenterol       Date:  2012-07-14       Impact factor: 5.742

4.  The tumor microenvironment in colorectal carcinogenesis.

Authors:  Vijay G Peddareddigari; Dingzhi Wang; Raymond N Dubois
Journal:  Cancer Microenviron       Date:  2010-03-05

5.  Voltage-gated Na+ channel SCN5A is a key regulator of a gene transcriptional network that controls colon cancer invasion.

Authors:  Carrie D House; Charles J Vaske; Arnold M Schwartz; Vincent Obias; Bryan Frank; Truong Luu; Narine Sarvazyan; Rosalyn Irby; Robert L Strausberg; Tim G Hales; Joshua M Stuart; Norman H Lee
Journal:  Cancer Res       Date:  2010-07-22       Impact factor: 12.701

6.  Osteopontin knockdown suppresses the growth and angiogenesis of colon cancer cells.

Authors:  Xin-Lin Wu; Kai-Jin Lin; Ai-Ping Bai; Wan-Xiang Wang; Xing-Kai Meng; Xiu-Lan Su; Ming-Xing Hou; Pei-De Dong; Jun-Jing Zhang; Zhao-Yang Wang; Lin Shi
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

7.  Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation.

Authors:  Subarna A Khan; Amy C Cook; Maya Kappil; Ursula Günthert; Ann F Chambers; Alan B Tuck; David T Denhardt
Journal:  Clin Exp Metastasis       Date:  2006-05-12       Impact factor: 5.150

8.  Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer.

Authors:  Wang Likui; Wang Hong; Zhang Shuwen
Journal:  J Gastrointest Surg       Date:  2009-09-18       Impact factor: 3.452

9.  Osteopontin is overexpressed in colorectal carcinoma and is correlated with P53 by immunohistochemistry.

Authors:  Jing Li; Guang-Zhi Yang; Zi-Man Zhu; Zhi-Yong Zhou; Lin Li
Journal:  Exp Ther Med       Date:  2012-01-30       Impact factor: 2.447

Review 10.  Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.

Authors:  Dong-Xing Cao; Zhi-Jie Li; Xiao-Ou Jiang; Yick Liang Lum; Ester Khin; Nikki P Lee; Guo-Hao Wu; John M Luk
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.